A New Combination Therapy Utilizing Mitochondria-Targeting Small-Molecule Ligands and Clinical Inhibitors against Melanoma

ACS Chemical Biology 2026

View at publisher
Authors: Ka-Hin Chan, Bo‐Xin Zheng, Yingying Zheng, Wen-De Zheng, Yao-Xun Zeng, Wei Long, Siyu Zhang, Ning Hou, Wenchang Yuan, Wing‐Leung Wong
DOI: 10.1021/acschembio.5c00562
Cited by: 2
References: 66

Abstract

with a clinical BRAF inhibitor (Vemurafenib, 0.2 μM) showed synergistic effects (CI = 0.67) against A375 cells. This new combined treatment significantly downregulates ATP production and glycolysis and induces acute senescence. The present study demonstrates an innovative and effective combination therapy strategy utilizing mitochondrion-targeting ligands and clinical inhibitors against melanoma.

Fields of Study & Subjects

Mitochondrial Function and Pathology Cancer Hypoxia and Metabolism ATP Synthase and ATPases Research

Publication details

Journal / source
ACS Chemical Biology
Publisher
American Chemical Society (ACS)
Volume
21
Issue
2
Pages
235–252
Publication date
21 January 2026
Language
EN